It showed that in patients with previously untreated stage IIIB to IV advanced NSCLC who were EGFR/ALK wild-type and with PD-L1 TPS≥1%, AK112 significantly prolonged their mPFS compared to pembrolizumab (11.14 vs. 5.82 months; HR, 0.51; p<0.0001), increasing their ORR (50.0% vs. 38.5%) and DCR (89.9% vs. 70.5%) (104). Here, ALK is linked to non-small cell lung carcinoma.